Abstract:Smoking is a major environmental factor causing nearly a third of cancer-related deaths. Nicotine accounts for 95% of tobacco's alkaloid content and 1.5% of the commercial cigarette products weight. With most cigarettes containing 1.2–2.9 mg of nicotine, heavy smokers can absorb 20–40 mg/day, resulting in plasma concentrations of 23–35 ng/ml. Nicotine exert potential oncogenic effects primarily through nicotinic acetylcholine receptors, without involving signal pathways or other receptors. Recent reviews have recognized the relationship between nicotine and a certain type of tumor. However, there is no systematic overview on the signal pathways related to nicotine via receptors or non-receptors in a variety of tumors. This review discusses emerging evidence of the relationship between cancer progression and nicotine. The list of cancers reportedly connected to nicotine is expanding and presently contains lung carcinoma, as well as cervical, colon, gastric, pancreatic, breast, liver, bladder, head and neck cancers including nasopharynx, tongue and oral cavity. There is growing evidence through the use of animal xenograft models and cell culture systems, that (1) nicotine's carcinogenic role stems from multiple signaling mechanisms, primarily involving both non-receptor-mediated actions and receptor-mediated effects, including nicotinic acetylcholine receptors, β-adrenergic receptors and epidermal growth factor receptors, as well as transforming growth factor β receptors; (2) nicotine could induce chromosomal abnormalities, DNA damage, and micronuclei formation; (3) nicotine also can enhance oxidative stress, leading to tumor initiation or progression due to excessive production of reactive oxygen species. Based on these findings, nicotine seems to be a potent oncogenic agent in modulating tumor cell proliferation, invasion and migration by various signaling pathways associated with chemical carcinogenicity.

A review on the effect of COX-2-mediated mechanisms on development and progression of gastric cancer induced by nicotine

Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: Involvement of nicotinic acetylcholine receptor (nAChR) and β-adrenergic receptor signaling pathways

Nicotine Enhances Invasion and Metastasis of Human Colorectal Cancer Cells Through the Nicotinic Acetylcholine Receptor Downstream P38 MAPK Signaling Pathway.

Activation of 5-Lipoxygenase is Required for Nicotine Mediated Epithelial-Mesenchymal Transition and Tumor Cell Growth

4‐(Methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone Promoted Gastric Cancer Growth Through Prostaglandin E Receptor (EP2 and EP4) in Vivo and in Vitro

Study on effect of cox-2 inhibitor on proliferation and invasion of human gastric cancer cells

Carcinogenicity of nicotine and signal pathways in cancer progression: a review

NF-κB Targets Mir-16 and Mir-21 in Gastric Cancer: Involvement of Prostaglandin E Receptors.

Chemoprevention of Cancers in Gastrointestinal Tract with Cyclooxygenase 2 Inhibitors

Molecular Mechanism for COX-2 in Carcinogenesis

Effects of Cyclooxygenase-2 in Tumor Invasion and Metastasis and Treatment

Research Progress of Cyclooxygenase-2 Inhibitors in Gastric Carcinoma

Nicotine May Promote Tongue Squamous Cell Carcinoma Progression by Activating the Wnt/β-catenin and Wnt/PCP Signaling Pathways

Nicotine Promotes the Development of Non-Small Cell Lung Cancer Through Activating LINC00460 and PI3K/Akt Signaling

Effect of NETs/COX-2 pathway on immune microenvironment and metastasis in gastric cancer

Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers

Understanding the Interaction Between Prostaglandins and Toll-Like Receptors in Nicotine-Induced Rectal Tumor in Animals

COX-2 Inhibitors and Gastric Cancer.

Cell signaling and epigenetic regulation of nicotine-induced carcinogenesis

Smoking and Cox-2 Functional Polymorphisms Interact to Increase the Risk of Gastric Cardia Adenocarcinoma in Chinese Population

Effects of chronic nicotine on the autocrine regulation of pancreatic cancer cells and pancreatic duct epithelial cells by stimulatory and inhibitory neurotransmitters